COMMUNIQUÉS West-GlobeNewswire

-
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
13/02/2025 - 22:01 -
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
13/02/2025 - 22:01 -
Bio-Path Holdings Expands Global Patent Portfolio
13/02/2025 - 22:01 -
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
13/02/2025 - 22:05 -
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/02/2025 - 22:05 -
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
13/02/2025 - 22:05 -
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
13/02/2025 - 22:05 -
ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference
13/02/2025 - 22:05 -
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
13/02/2025 - 22:05 -
ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call
13/02/2025 - 22:05 -
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day
13/02/2025 - 22:05 -
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
13/02/2025 - 22:05 -
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
13/02/2025 - 22:15 -
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
13/02/2025 - 22:30 -
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
13/02/2025 - 22:30 -
Precision Optics Reports Second Quarter Fiscal Year 2025 Financial Results
13/02/2025 - 22:30 -
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
13/02/2025 - 22:30 -
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
13/02/2025 - 22:30 -
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
13/02/2025 - 22:34
Pages